Anti-Fas Antibody (human, activating), clone CH11

Description

• General description: Fas/APO-1/CD95 (36 kDa) is a member of the tumor necrosis factor (TNF) receptor superfamily, a family of transmembrane receptors. Fas has been shown to be an important mediator of apoptotic cell death, as well as being involved in inflammation. Binding of the Fas ligand (Fas-L) induces trimerization of Fas in the target cell membrane. Activation of Fas causes the recruitment of Fas-associated protein with death domain (FADD) via interactions between the death domains of Fas and FADD. Procaspase 8 binds to Fas-bound FADD via interactions between the death effector domains (DED) of FADD and pro-caspase 8 leading to the activation of caspase 8. Activated caspase 8 cleaves (activates) other procaspases, in effect beginning a caspase cascade that ultimately leads to apoptosis. Caspases cleave nuclear lamins, causing the nucleus to break down and lose its normal structure. Fas-induced apoptosis can be effectively blocked at several stages by either FLICE-inhibitory protein (FLIP), by Bcl-2, or by the cytokine response modifier A (CrmA).Biological ActivityThe antibody demonstrates cytolytic activity on human cells that express Fas. Murine WR19L cells and L929 cells transfected with cDNA encoding human Fas undergo apoptosis in response to this antibody.
• Specificity: This antibody does not recognize TNF, and does not cross-react with mouse Fas. Fas ligand will induce apoptosis in human, mouse and rat systems.
• Immunogen: FS-7 (human diploid fibroblast cell line). Clone CH-11.
• Application: Detect Fas using this Anti-Fas Antibody (human, activating), clone CH11 has been published and validated for use in Flow Cytometry (FC), Immunocytochemistry (IC) and Western Blot (WB).
• Quality: Routinely evaluated by demonstrating cytolytic activity on human cells that express Fas. Murine WR19L cells and L929 cells transfected with cDNA encoding human Fas undergo apoptosis in response to this antibody.Apoptosis Assay Analysis: 15-20 µg/mL of this lot maximally induced apoptosis of human Jurkat cells with 83% mortality after 24 hours of treatment.
• Target description: 43 kDa
• Physical form: Immunoaffinity Chromatography
• Storage and Stability: Stable for 1 year at -20°C from date of receipt. For maximum recovery of the product, centrifuge the original vial prior to removing the cap.
• Analysis Note: ControlHuman liver tumor, human breast tumor or Jurkat whole cell lysate, Raji cell lysate.
• Other Notes: Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
• Legal Information: UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.